These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19671026)

  • 1. Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.
    Yu Z; Ren P; Zhang X; Zhang T; Ma B
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1065-71. PubMed ID: 19671026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
    Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic approach?
    Haenssle HA
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1240-5. PubMed ID: 16370389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future directions for immunotherapeutic intervention against sarcomas.
    Maki RG
    Curr Opin Oncol; 2006 Jul; 18(4):363-8. PubMed ID: 16721132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK; Ueno H; Fay JW; Banchereau J
    Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dendrite cell-based cancer vaccines--clinical application].
    Svane IM; Berntsen A; Trepiakas R; Pedersen AE
    Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
    Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
    Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reengineering dendritic cell-based anti-cancer vaccines.
    Koski GK; Cohen PA; Roses RE; Xu S; Czerniecki BJ
    Immunol Rev; 2008 Apr; 222():256-76. PubMed ID: 18364007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell immunotherapy: mapping the way.
    Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
    Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.